A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

Bleeding Clinical Trial

Official title:

A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02047565
• Other study ID #: DU176b-A-U158
• Status: Completed
• Phase: Phase 1
• Start date: October 2013
• Est. completion date: May 2014

Study information

• Verified date: January 2015
• Source: Daiichi Sankyo, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1 study consists of 2 parts. Part 1 will be an open-label, randomized, 2 treatment, 2-way crossover study. Part 2 will be a double-blind (Sponsor unblinded), randomized, placebo controlled, sequential descending prothrombin complex concentrate dose, 2 sequence, 2 period crossover study. In both parts of the study, the assessor of BD and BV will remain blinded. In Part 2 of the study, both the subject and the clinic staff involved in study conduct will be blinded (with the exception of the pharmacist or nurse who prepares the blinded individual treatments from open-label supplies). The study programmer and statistician will also be blinded to treatment assignment. The Sponsor will remain unblinded for both parts of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy subjects between 18 and 45 years of age, with a body mass index between 18 and 30 kg/m2, and weighing = 110 kg.

Exclusion Criteria:

• Women of childbearing potential without proper contraceptive measures and women who are pregnant or breastfeeding. Women of childbearing potential who participate in the study must agree to use proper contraceptive measures from screening through 13 weeks after the last dose of study drug.

• Subjects with history of unexplained syncope. Subjects who have prior clearance of vasovagal events may be included.

• Subjects who have used any drugs or substances known to be strong inhibitors or strong inducers of cytochrome P450 (CYP) 3A4/5 enzymes or P-glycoprotein within 28 days prior to the first dosing.

• Subjects who have used any other nonprescription drugs (including herbal supplemental), except acetaminophen (up to 3 g/day) within 14 days prior to check-in.

• Subjects with history of major bleeding, major trauma, or major surgical procedure of any type within 6 months of dosing.

• Subjects with history of peptic ulcer, gastrointestinal bleeding (including hematemesis, melena, and rectal bleeding), or bleeding from hemorrhoids.

• Subjects with history of minor bleeding episodes such as epistaxis, rectal bleeding (spots of blood on toilet paper), and gingival bleeding within 3 months before the first dose.

• Subjects who have any family history, suspected or documented, of coagulopathy.

• Subjects who have participated in a previous edoxaban study within 6 months prior to the first dose.

• Subjects who used anticoagulants (eg, warfarin, low molecular weight heparin), antiplatelet agents (eg, clopidogrel), non-steroidal anti-inflammatory drugs, and/or acetylsalicylic acid 30 days prior to punch biopsy or who expect to use these during the study.

• Subjects with hemoglobin levels below 12 g/dL (men) or 11 g/dL (women) at screening.

• Subjects with creatinine clearance = 80 mL/min (based on the Cockcroft-Gault equation).

• Subjects who are considered inappropriate for the punch biopsy procedure based on inability to visualize surface blood vessels, and history or likelihood of forming keloid scars.

• Subjects with known heparin-induced thrombocytopenia.

• Subjects who have a platelet count, PT, or INR outside of the normal range at baseline.

• Subjects with history or current evidence of clinically significant cardiac, hepatic, renal, pulmonary, endocrine, neurologic, infectious, gastrointestinal, hematologic, or oncologic disease as determined by screening history, physical examination, laboratory test results, or 12-lead electrocardiogram (ECG).

In addition, for Part 2:

• Subjects who are deficient in Factor V Leiden mutation.

• Subjects who are deficient in protein S, protein C, antithrombin, or factor II, or have prothrombin 20210A mutation.

• Subjects with known anaphylactic or severe systemic reactions to Beriplex P/N or any components in Beriplex P/N including heparin; FII, FVII, FIX, and FX; proteins C and S; antithrombin III; and human albumin.

• Subjects with current or history of disseminated intravascular coagulation.

Related Conditions & MeSH terms

• Bleeding
• Hemorrhage

Intervention

Drug:
• 60mg edoxaban

• 180mg edoxaban

• 50 IU/kg Beriplex P/N

• 25 IU/kg Beriplex P/N

• 10 IU/kg Beriplex P/N

Locations

Country	Name	City	State
United States	Quintiles	Overland Park	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Daiichi Sankyo, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bleeding duration 60mg edoxaban	To assess the variability and effect size of bleeding duration (BD) following punch biopsy in healthy subjects administered 60 mg edoxaban	Day 1
Primary	Bleeding volume 60mg edoxaban	To assess the variability and effect size of bleeding volume (BV) following punch biopsy in healthy subjects administered 60 mg edoxaban	Day 1
Primary	Bleeding duration 180mg edoxaban	To assess the variability and effect size of bleeding duration (BD) following punch biopsy in healthy subjects administered 180 mg edoxaban	Day 1
Primary	Bleeding volume 180mg edoxaban	To assess the variability and effect size of bleeding volume (BV) following punch biopsy in healthy subjects administered 180 mg edoxaban	Day 1
Secondary	Prothrombin Time	To evaluate the reversal of the effect of 60 mg edoxaban on Prothrombin Time (PT), International Normalized Ratio (INR), Activated Partial Thromboplastin Time (aPTT), and Thrombin Generation Assay (TGA) parameters by Beriplex P/N	Day 1
Secondary	International Normalized Ratio	To evaluate the reversal of the effect of 60 mg edoxaban on Prothrombin Time (PT), International Normalized Ratio (INR), Activated Partial Thromboplastin Time (aPTT), and Thrombin Generation Assay (TGA) parameters by Beriplex P/N	Day 1
Secondary	Activated Partial Thromboplastin Time	To evaluate the reversal of the effect of 60 mg edoxaban on Prothrombin Time (PT), International Normalized Ratio (INR), Activated Partial Thromboplastin Time (aPTT), and Thrombin Generation Assay (TGA) parameters by Beriplex P/N	Day 1
Secondary	Thrombin Generation Assay	To evaluate the reversal of the effect of 60 mg edoxaban on Prothrombin Time (PT), International Normalized Ratio (INR), Activated Partial Thromboplastin Time (aPTT), and Thrombin Generation Assay (TGA) parameters by Beriplex P/N	Day 1
Secondary	procoagulant markers D dimer	To evaluate the effects of Beriplex P/N following 60 mg edoxaban on the procoagulant markers D dimer and prothrombin fragment F1 + 2 (F1 + 2)	Day 1
Secondary	prothrombin fragment F1 + 2	To evaluate the effects of Beriplex P/N following 60 mg edoxaban on the procoagulant markers D dimer and prothrombin fragment F1 + 2 (F1 + 2)	Day 1
Secondary	coagulation factor concentrations	To evaluate the effects of Beriplex P/N following 60 mg edoxaban on coagulation factor concentrations	Day 1
Secondary	cmax of edoxaban and its active metabolite, D21-2393	To evaluate single dose pharmacokinetics (PK) of edoxaban and its active metabolite, D21-2393	Day 1
Secondary	tmax of edoxaban and its active metabolite, D21-2393	To evaluate single dose pharmacokinetics (PK) of edoxaban and its active metabolite, D21-2393	Day 1
Secondary	AUC 0-24 of edoxaban and its active metabolite, D21-2393	To evaluate single dose pharmacokinetics (PK) of edoxaban and its active metabolite, D21-2393	Day 1